4/24
06:03 pm
rvmd
Ben Sasse was given a few months to live. He credits "providence, prayer and a miracle drug" for giving him more time. [CBS News]
Low
Report
Ben Sasse was given a few months to live. He credits "providence, prayer and a miracle drug" for giving him more time. [CBS News]
4/22
10:30 am
rvmd
Revolution Medicines (RVMD) had its price target raised by Leerink Partners from $147.00 to $171.00. They now have an "outperform" rating on the stock.
Low
Report
Revolution Medicines (RVMD) had its price target raised by Leerink Partners from $147.00 to $171.00. They now have an "outperform" rating on the stock.
4/22
08:07 am
rvmd
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $169.00 price target on the stock.
Medium
Report
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $169.00 price target on the stock.
4/21
05:35 pm
rvmd
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
Medium
Report
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
4/21
05:30 pm
rvmd
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
Medium
Report
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
4/21
11:23 am
rvmd
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
Low
Report
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
4/20
10:58 am
rvmd
AACR 2026: Revolution's next prospect, Merck's reveal and a lung cancer battle [Yahoo! Finance]
Low
Report
AACR 2026: Revolution's next prospect, Merck's reveal and a lung cancer battle [Yahoo! Finance]
4/20
09:24 am
rvmd
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $215.00 price target on the stock, up from $170.00.
Medium
Report
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $215.00 price target on the stock, up from $170.00.
4/20
07:41 am
rvmd
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]
Medium
Report
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]
4/20
07:04 am
rvmd
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]
Medium
Report
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]
4/19
09:18 pm
rvmd
Revolution Medicines (RVMD) Jumps 54% on Stellar Drug Trial Results [Yahoo! Finance]
Low
Report
Revolution Medicines (RVMD) Jumps 54% on Stellar Drug Trial Results [Yahoo! Finance]
4/19
02:08 pm
rvmd
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting [Yahoo! Finance]
Low
Report
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting [Yahoo! Finance]
4/19
02:00 pm
rvmd
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
Low
Report
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
4/19
12:43 am
rvmd
Jim Cramer Shares Why Revolution Medicines (RVMD) is Extraordinary [Yahoo! Finance]
Low
Report
Jim Cramer Shares Why Revolution Medicines (RVMD) is Extraordinary [Yahoo! Finance]
4/17
04:02 pm
rvmd
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
4/16
10:13 am
rvmd
Revolution Medicines Doubles Stock Offering Target to $2 Billion Following Pancreatic Cancer Breakthrough [TheStreet.com]
Low
Report
Revolution Medicines Doubles Stock Offering Target to $2 Billion Following Pancreatic Cancer Breakthrough [TheStreet.com]
4/16
03:43 am
rvmd
Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data [Yahoo! Finance]
Low
Report
Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data [Yahoo! Finance]
4/15
06:16 am
rvmd
Revolution Medicines prices $2B in concurrent stock, notes offerings [Seeking Alpha]
Medium
Report
Revolution Medicines prices $2B in concurrent stock, notes offerings [Seeking Alpha]
4/15
01:29 am
rvmd
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes [Yahoo! Finance]
Medium
Report
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes [Yahoo! Finance]
4/15
12:41 am
rvmd
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
Medium
Report
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
4/14
11:10 am
rvmd
Revolution Medicines (RVMD) had its price target raised by Wells Fargo & Company from $144.00 to $167.00. They now have an "overweight" rating on the stock.
Low
Report
Revolution Medicines (RVMD) had its price target raised by Wells Fargo & Company from $144.00 to $167.00. They now have an "overweight" rating on the stock.
4/14
10:16 am
rvmd
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Wedbush. They now have a $147.00 price target on the stock.
Medium
Report
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Wedbush. They now have a $147.00 price target on the stock.
4/14
08:57 am
rvmd
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Evercore Inc.
Medium
Report
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Evercore Inc.
4/14
08:04 am
rvmd
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Medium
Report
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
4/14
08:04 am
rvmd
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Guggenheim.
Medium
Report
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Guggenheim.